Arbutus Biopharma (ABUS) Total Non-Current Liabilities (2011 - 2026)

Arbutus Biopharma has disclosed Total Non-Current Liabilities across 16 years of filings, most recently posting $8.4 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $8.4 million, down 69.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.4 million (down 69.33% YoY), and the FY2025 annual result was $14.6 million, down 39.46% from the prior year.
• Total Non-Current Liabilities came in at $8.4 million for Q1 2026 at Arbutus Biopharma, down from $14.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $67.4 million in Q1 2022 to a low of $8.4 million in Q1 2026.
• The 5-year median for Total Non-Current Liabilities is $29.6 million (2024), against an average of $31.5 million.
• Across the five-year window, Total Non-Current Liabilities surged 429.71% in 2022 and tumbled 69.33% in 2026, its largest moves.
• Arbutus Biopharma's Total Non-Current Liabilities stood at $48.2 million in 2022, then sank by 36.14% to $30.8 million in 2023, then dropped by 21.66% to $24.1 million in 2024, then tumbled by 39.46% to $14.6 million in 2025, then plunged by 42.58% to $8.4 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $8.4 million (Q1 2026), $14.6 million (Q4 2025), and $16.6 million (Q3 2025), per Business Quant data.